The Liver Meeting 2019-Hepatitis Debrief

Video Transcription

Video Summary

Dr. Mark Ghani from NIDDK, Liver Diseases Branch, presented on hepatitis B and C infections, discussing therapeutics, prevention, and factors affecting liver disease progression. For hepatitis B, data showed the impact of non-alcoholic fatty liver disease on liver injury and the comparison of HCC risk between tenofovir and entecavir. Studies also explored using anti-platelet therapy to reduce HCC risk in virally suppressed patients. Therapeutic approaches focused on achieving functional cure using surface antigen loss as an endpoint and exploring novel agents like core assembly modulators. For hepatitis C, efforts were directed towards elimination, with studies on treating challenging populations like persons who inject drugs and the impact of SVR on liver-related and extrahepatic outcomes. Advances were also made in pediatric treatment options and utilizing HCV-positive organ donors for HCV-negative recipients, with promising results in preventing post-transplant infections. These findings highlight the progress in managing and preventing hepatitis B and C infections, enhancing treatment outcomes, and working towards elimination goals.

Asset Caption

Presenter: Marc G. Ghany

Keywords

hepatitis B

hepatitis C

therapeutics

prevention

liver disease progression

HCC risk

elimination